Clinical trial · Observational
Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)
Durvalumab as Consolidation Therapy After Concurrent Chemoradiotherapy (cCRT) for Patients With Limited-stage Small-cell Lung Cancer (LS-SCLC): A Retrospective, Single-center, Real-world Cohort Study
NCT07050472CI-TRIAL-00103190completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small-cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- LS-SCLC
Primary outcomes (1)
- measure
- rwPFS
- timeFrame
- Up to 60 months
- description
- From the start of Durvalumab treatment to disease progression (tumor assessed by investigator) or death for any reason
Secondary outcomes (3)
- measure
- DoT
- timeFrame
- Up to 60 months
- description
- Time from the start of Durvalumab treatment to the date of durvalumab discontinuation or death
- measure
- real-world progression free survival rate at 24 months(rwPFS24)
- timeFrame
- 24 months after first dose of durvalumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged ≥18 at initial diagnosis. 2. Histologically or cytologically documented limited-stage SCLC (Stage I-III SCLC \[T any, N any, M0\] according to the American Joint Committee on Cancer Staging Manual \[AJCC Cancer Staging Manual, 9th Edition\] or the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology \[IASLC Staging Manual in Thoracic Oncology 2016\]). 3. Received concurrent chemoradiotherapy (cCRT) as first-line treatment and consolidative durvalumab prior to disease progression or death: * Received 4 cycles of platinum-based chemotherapy concurrent with radiotherapy. * The chemotherapy regimen must contain carboplatin/cisplatin and etoposide. * Received a total dose of radiation of 60 to 66 Gy over 6 weeks for standard QD radiation schedules, 45 Gy over 3 weeks or a simultaneous integrated boost of 54 Gy over 3 weeks for hyperfractionated BID radiation schedules. * Radiotherapy must have commenced no later than the end of Cycle 2 of chemotherapy. * Received at least 1 dose of durvalumab. The first dose of durvalumab received between 1 Jan 2020 and 31 Dec 2023 at Peking University Cancer Hospital. Exclusion Criteria: 1. Mixed SCLC and NSCLC histology. 2. Participated in other interventional clinical trial for the treatment of any cancer during durvalumab therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.